NASDAQ:IMVT

Immunovant (IMVT) Stock Price, News & Analysis

Immunovant logo
$31.77 -0.75 (-2.31%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$31.67 -0.10 (-0.31%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Immunovant Stock (NASDAQ:IMVT)

Advanced

Key Stats

Today's Range
$31.61
▼
$32.77
50-Day Range
$26.73
▼
$37.66
52-Week Range
$21.86
▼
$45.42
Volume
704,202 shs
Average Volume
1.36 million shs
Market Capitalization
$6.57 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.60
Consensus Rating
Moderate Buy

Company Overview

Immunovant, Inc. is a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases. Its research focuses on inhibiting the neonatal Fc receptor (FcRn), a pathway involved in maintaining levels of disease-causing antibodies.

The company’s investigational medicines include batoclimab and IMVT-1402, both designed to reduce circulating antibodies. Immunovant has studied or evaluated these candidates for conditions including myasthenia gravis, Graves’ disease and other autoimmune disorders. Its medicines are investigational and are not approved for commercial use.

Immunovant was launched by Roivant Sciences in 2018 and remains part of the Roivant group. The company is led by President and Chief Executive Officer Peter Salzmann.

AI Generated. May Contain Errors.

Immunovant Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
44th Percentile Overall Score

IMVT MarketRank™: 
2.181320992845 of 5 stars

Immunovant scored higher than 44% of companies evaluated by MarketBeat, and ranked 566th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Immunovant has received a consensus rating of Moderate Buy. The company's average rating score is 2.62, and is based on no strong buy ratings, 9 buy ratings, 3 hold ratings, and 1 sell rating.

  • Upside Potential

    Immunovant has a consensus price target of $44.60, representing about 40.4% upside from its current price of $31.77.

  • Amount of Analyst Coverage

    Immunovant has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Immunovant's stock forecast and price target.
  • Earnings Growth

    Earnings for Immunovant are expected to decrease in the coming year, from ($2.49) to ($2.68) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Immunovant is -12.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Immunovant is -12.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Immunovant has a P/B Ratio of 10.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Immunovant's valuation and earnings.
  • Percentage of Shares Shorted

    9.15% of the float of Immunovant has been sold short.
  • Short Interest Ratio / Days to Cover

    Immunovant has a short interest ratio ("days to cover") of 15.26, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Immunovant has recently increased by 1.51%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Immunovant does not currently pay a dividend.

  • Dividend Growth

    Immunovant does not have a long track record of dividend growth.

  • News Sentiment

    Immunovant has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Immunovant this week, compared to 4 articles on an average week.
  • Search Interest

    Only 4 people have searched for IMVT on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Immunovant insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $895,852.00 in company stock.

  • Percentage Held by Insiders

    1.90% of the stock of Immunovant is held by insiders.

  • Percentage Held by Institutions

    47.08% of the stock of Immunovant is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Immunovant's insider trading history.
Receive IMVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IMVT Stock News Headlines

Immunovant Stock Gets Higher EPS Forecast from HC Wainwright
Immunovant (NASDAQ:IMVT) Upgraded to "Hold" at Wall Street Zen
CFA: Bank of America Said THIS
On January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.tc pixel
Immunovant (IMVT) Q2 2027 Earnings Call Transcript
Immunovant, Inc. (IMVT) Q2 2027 Earnings Call Transcript
See More Headlines

IMVT Stock Analysis - Frequently Asked Questions

Immunovant's stock was trading at $25.42 at the start of the year. Since then, IMVT stock has increased by 25.0% and is now trading at $31.77.

Immunovant, Inc. (NASDAQ:IMVT) posted its quarterly earnings data on Monday, November, 9th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.27.
Read the conference call transcript
.

Immunovant's top institutional investors include Two Seas Capital LP (2.23%), State Street Corp (2.03%), Baker BROS. Advisors LP (1.34%) and Goldman Sachs Group Inc. (0.77%). Insiders that own company stock include Sciences Ltd Roivant, Peter Salzmann, Julia G Butchko, Eva Renee Barnett, William L Macias, Mark S Levine, Eric Venker, Tiago Girao, Michael Geffner, Melanie Gloria, Jay S Stout, Tuyl Christopher Van, Douglas J Hughes, Atul Pande, Andrew J Fromkin and Robert Graham Susman.
View institutional ownership trends
.

Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Immunovant investors own include NVIDIA (NVDA), Viking Therapeutics (VKTX), Micron Technology (MU), Grifols (GRFS), Li Auto (LI), Palantir Technologies (PLTR) and Plug Power (PLUG).

Company Calendar

Last Earnings
11/09/2026
Today
11/22/2026
Investor Day 2026
12/09/2026
Next Earnings (Estimated)
2/05/2027
Fiscal Year End
3/31/2027

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:IMVT
CIK
1764013
Fax
N/A
Employees
315
Year Founded
2018

Price Target and Rating

High Price Target
$62.00
Low Price Target
$28.00
Potential Upside/Downside
+40.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.62
Research Coverage
13 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.56)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$505.61 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-63.01%
Return on Assets
-56.19%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.31
Quick Ratio
7.31

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.17 per share
Price / Book
10.02

Miscellaneous

Outstanding Shares
206,948,000
Free Float
203,016,000
Market Cap
$6.57 billion
Optionable
Optionable
Beta
0.95

Social Links

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (NASDAQ:IMVT) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners